121660-37-5

Basic information

• Product Name: 2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde
• Synonyms: 2-CYCLOPROPYL-4-(4-FLUOROPHENYL)QUINOLINE-3-CARBALDEHYDE;2-Cyclopropyl-4-(4-fluorophenyl)-3-Quinolinecarboxaldehyde;3-MethylBr- 2-Cyclopropyl-4-(4-Fluorophenyl) -Quinolyl;2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde;2-CYCLOPROPYL-4-(4-FLUOROPHENYL)QUINOLINE-3-CARBALDEHYDE, 96+%;4-(4-FLUOROPHENYL)-2-(CYCLOPROPYL)-3-QUINOLINECARBOXALDEHYDE;2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxaldehyde;2-Cyclopropyl-4-(4-fluoropenyl)v-quinolyl-3-carboxaldehyde
• CAS NO: 121660-37-5
• Molecular Formula: C₁₉H₁₄FNO
• Molecular Weight: 291.32
• EINECS: 1308068-626-2
• Product Categories: Pitavastatin Calcium and its intermediates;Pitavastatin Calcium Intermediates
• Mol File: 121660-37-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 453.928 ºC at 760 mmHg
• Flash Point: 228.328 ºC
• Appearance: /
• Density: 1.289 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 3.69±0.50(Predicted)
• CAS DataBase Reference: 2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde(121660-37-5)
• EPA Substance Registry System: 2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde(121660-37-5)

Safety Data

• Hazardous Substances Data: 121660-37-5(Hazardous Substances Data)

Usage

Uses

2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde is an intermediate used in the synthesis of NK-104.

Upstream product

• 477950-34-8 ethyl (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoate 
• 148516-11-4 2-cyclopropyl-4-(4-fluoro-phenyl)-3-quinoline carboxylic acid ethyl ester 
• 462-06-6 fluorobenzene 
• 552-16-9 ortho-nitrobenzoic acid 
• 120303-62-0 (4-fluorophenyl)(2-nitrophenyl)methanone 
• 765-43-5 Cyclopropyl methyl ketone 
• 1356998-79-2 2-cyclopropyl-4-(4-fluorophenyl)-3-methylquinoline 
• 154057-56-4 3-(bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)-quinoline 
• 6704-19-4 1-cyclopropylpropan-1-one 
• 110-91-8 morpholine 
• 121659-86-7 methyl 4-(4'-fluorophenyl)-2-cyclopropylquinoline-3-carboxylate 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 3800-06-4 2-amino-4'-fluorobenzophenone 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 

Downstream Products

• 141750-56-3 (E)-3-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-N-methoxy-N-methyl-acrylamide 
• 155849-96-0 N-methoxy-N-methyl3-<2-cyclopropyl-4-(4-fluorophenyl)quinolin-2-yl>-3-hydroxypropanamide 
• 256431-72-8 (E)-3-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-2-propenenitrile 
• 391681-95-1 2-cyclopropyl-3-(3-ethoxy-1-hydroxy-2-propenyl)-4-(4-fluorophenyl)quinoline 
• 148901-68-2 (E)-3-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-propenal 
• 148901-69-3 (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-5-hydroxy-3-oxohept-6-enic acid ethyl ester 
• 172336-32-2 (±)-E-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-6-heptenoic acid ethyl ester 
• 172336-32-2 ethyl (E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]hept-6-enoate 
• 254452-86-3 (E)-(3S,5R)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid 
• 147526-32-7 pitavastatin 
• 254452-94-3 (E)-(R)-5-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3-hydroxy-pent-4-enoic acid methyl ester 
• 254452-90-9 (E)-(S)-5-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3-hydroxy-pent-4-enoic acid methyl ester 
• 147511-69-1 (E)-(3R,5R)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid 
• 147511-69-1 (E)-(3S,5S)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid 

Relevant articles and documents

Preparation method of pitavastatin calcium intermediate

The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of a pitavastatin calcium intermediate. The preparation method comprises the following steps: 1,carrying out a chemical reaction on a compound II and triphenylphosphine at a temperature of 10-150 DEG C to prepare a compound III; 2, in the presence of triethylamine, with oxalyl chloride and dimethyl sulfoxide as oxidants, subjecting a compound IV to a chemical reaction to prepare a compound V; and 3, subjecting the compound III and the compound V to a chemical reaction at 20-150 DEG C in thepresence of a basic catalyst so as to prepare a compound I. The intermediate prepared by using the method provided by the invention has the advantages of easy availability of raw materials, simple operation, high yield and high purity. The specific synthetic route of the method is shown in the specification.

Palladium-Catalyzed Carbonylative Couplings of Vinylogous Enolates: Application to Statin Structures

The first Pd-catalyzed carbonylative couplings of aryl and vinyl halides with vinylogous enolates are reported generating products derived from C-C bond formation exclusively at the γ-position. Good results were obtained with a dienolate derivative of acetoacetate (1,3-dioxin-4-one). These transformations occurred at room temperature and importantly with only stoichiometric carbon monoxide in a two-chamber reactor. The methodology was applied to the synthesis of two members of the statin family generating the cis-3,5-diol acid motif by a γ-selective carbonylation followed by a cis-stereoselective reduction of the 3,5-dicarbonyl acid intermediates.

PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.